The day when PlasmaGen BioSciences laid down its foundation stone. And there lied the “Genesis” of India’s first Plasma Protein Therapeutics focused company.
Starts buildingup team and makes its first international representation at the Plasma Product Biotechnology (PPB) meet in Cyprus.
Launches its first product in the Indian market, ‘RonsenGlob’ - Intravenous Immunoglobulin.
In the same year, it launches its pipeline product ‘PlasmaHep’ – Hepatitis B Immunoglobulin, which in the Indian scenario was an imperative addition propelling the prophylactic prevention of Hepatitis B.
Participates in a global event in the World Health Organization (WHO) to discuss “Plasma Product Scenario in India.
Becomes one of the very few biopharmaceutical companies in India to obtain the license for Plasma Collection from various blood banks of India & production of plasma products from the Regulatory Authorities of India
Conceptualized, and was instrumental in Organizing, Planning & Execution of the 1st BioplasmaWorld Asia Conference held in Hong Kong.
Actively participated in developing and execution of Haemovigilance Program in India.
PlasmaGen launched its double viral inactivated Intravenous Immunoglobulin under its brand name ‘PlasmaGlob’.
Later in 2013, understanding the need of Albumin in India, PlasmaGen launched ‘AlbuMax’- 20% Albumin solution. The product gained immediate acceptance.
PGB’s active contribution at IXth Annual Conference of South Asian Association of Transfusion Medicine, Gurgaon, New Delhi.
Very actively participated in conceptualization and formulation of country’s National Policy for Access to Plasma Derived Medicinal Products from Human Plasma for Clinical / Therapeutic Use
With a vision to provide Indian patients with the maximum range of Plasma Products, PlasmaGen launched two major hyperimmunes- ‘PlasmaRho-I.M.’ – Anti-D Immunoglobulin for Rh incompatibility & maternal sensitization and ‘PlasmaRab’ – Anti Rabies Immunoglobulin for the rabies prophylaxis.
Worked with Indian pharmacopoeia in formulating the plasma product monograph.
Worked with National Pharmaceutical Pricing Authority towards rationalizing the price of Plasma products
Launch of Verbumin - additional variant of Albumin to be able to meet the increasing need of albumin in the country.
Launch of PlasmaRho-D I.V. with an intent to cater to patients with a therapy that entails at par efficacy and higher affordability.
Participated in State of Art Multiple Myeloma conference held in Chandigarh.
Hosted an international Symposium on the topic “Realizing the potential of Anti-D I.V. in Haematology” at Haematocon conference held in Jaipur.
Funded by Fidelity Eight Road Ventures.
PlasmaGen expanded its product portfolio with the largest field force in the country, spanning across 70+ Cities, 700+ Hospitals & 7000+ Clinicians.
PlasmaGen BioSciences now possess one of the largest field force of 80 people in plasma protein industry spanning across the country, with the widest range of plasma products in India.